Advertisement

Comparison of Outcomes and Usefulness of Carvedilol Across a Spectrum of Left Ventricular Ejection Fractions in Patients With Heart Failure in Clinical Practice

      Heart failure (HF) in the community differs meaningfully from that in clinical trials, particularly the higher prevalence of patients with preserved left ventricular (LV) ejection fraction (EF) typically excluded from clinical trials, thus limiting knowledge of their responsiveness to β-blocker therapy. From a community-based registry of 4,280 patients with HF starting treatment with the β blocker carvedilol, we compared characteristics, carvedilol titration, and outcomes of patients according to LVEF >40% or <40% (as in clinical trials) and across the spectrum of LVEF <21%, 21% to 30%, 31% to 40%, and >40%. Patients with preserved EF (LVEF >40%) were older and more often women and hypertensive. Lower LVEF was associated with worse functional class and more HF hospitalizations in the previous year. Carvedilol dose decreased with increasing LVEF. Hospitalization rates for HF related inversely to LVEF before starting carvedilol therapy and decreased from the previous year in all LVEF groups during follow-up. Although 1-year mortality rate decreased from 8% with LVEF ≤20% to 6% with LVEF >40%, adjusted hazard ratios were not significantly different across LVEF groups. Thus, characteristics of community patients with HF vary across the spectrum of LVEF. Patients with HF and preserved EF treated with carvedilol in the community improve symptomatically and experience fewer HF hospitalizations after initiating carvedilol. In conclusion, without a control group, the effect of carvedilol on outcomes is not conclusive and trials of carvedilol in patients with HF and preserved EF should be undertaken.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Philbin E.F.
        • Rocco Jr, T.A.
        • Lindenmuth N.W.
        • Ulrich K.
        • Jenkins P.L.
        Clinical outcomes in heart failure: report from a community hospital-based registry.
        Am J Med. 1999; 107: 549-555
        • Chin M.H.
        • Friedmann P.D.
        • Cassel C.K.
        • Lang R.M.
        Differences in generalist and specialist physicians’ knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure.
        J Gen Intern Med. 1997; 12: 523-530
        • Edep M.E.
        • Shah N.B.
        • Tateo I.M.
        • Massie B.M.
        Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines.
        J Am Coll Cardiol. 1997; 30: 518-526
        • Hogg K.
        • Swedberg K.
        • McMurray J.
        Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis.
        J Am Coll Cardiol. 2004; 43: 317-327
        • Lenzen M.J.
        • Scholte op Reimer W.J.
        • Boersma E.
        • Vantrimpont P.J.
        • Follath F.
        • Swedberg K.
        • Cleland J.
        • Komajda M.
        Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey.
        Eur Heart J. 2004; 25: 1214-1220
        • Ansari M.
        • Alexander M.
        • Tutar A.
        • Massie B.M.
        Incident cases of heart failure in a community cohort: importance and outcomes of patients with preserved systolic function.
        Am Heart J. 2003; 146: 115-120
        • Masoudi F.A.
        • Havranek E.P.
        • Smith G.
        • Fish R.H.
        • Steiner J.F.
        • Ordin D.L.
        • Krumholz H.M.
        Gender, age, and heart failure with preserved left ventricular systolic function.
        J Am Coll Cardiol. 2003; 41: 217-223
        • Franciosa J.A.
        • Massie B.M.
        • Lukas M.A.
        • Nelson J.J.
        • Lottes S.
        • Abraham W.T.
        • Fowler M.
        • Gilbert E.M.
        • Greenberg B.
        • COHERE Participant Physicians
        Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry.
        Am Heart J. 2004; 148: 718-726
        • Franciosa J.A.
        • Abraham W.T.
        • Fowler M.
        • Gilbert E.M.
        • Greenberg B.
        • Massie B.M.
        • Chen T.
        • Lukas M.A.
        • Nelson J.J.
        • COHERE Participant Physicians
        Rationale, design, and methods for a Coreg (carvedilol) heart failure registry (COHERE).
        J Card Fail. 2000; 6: 264-271
        • Greenberg B.
        • Lottes S.R.
        • Nelson J.J.
        • Lukas M.A.
        • Fowler M.B.
        • Massie B.M.
        • Abraham W.T.
        • Gilbert E.M.
        • Franciosa J.A.
        • COHERE Participant Physicians
        Predictors of clinical outcomes in patients given carvedilol for heart failure.
        Am J Cardiol. 2006; 98: 1480-1484
        • Zile M.R.
        • Baicu C.F.
        • Gaasch W.H.
        Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle.
        N Engl J Med. 2004; 350: 1953-1959
        • Yusuf S.
        • Pfeffer M.A.
        • Swedberg K.
        • Granger C.B.
        • Held P.
        • McMurray J.J.
        • Michelson E.L.
        • Olofsson B.
        • Ostergren J.
        • CHARM Investigators and Committees
        Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
        Lancet. 2003; 362: 777-781
        • Flather M.D.
        • Shibata M.C.
        • Coats A.J.
        • Van Veldhuisen D.J.
        • Parkhomenko A.
        • Borbola J.
        • Cohen-Solal A.
        • Dumitrascu D.
        • Ferrari R.
        • Lechat P.
        • et al.
        • SENIORS Investigators
        Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).
        Eur Heart J. 2005; 26: 215-225
        • Packer M.
        • Bristow M.R.
        • Cohn J.N.
        • Colucci W.S.
        • Fowler M.B.
        • Gilbert E.M.
        • Shusterman N.H.
        • for the U.S.
        Carvedilol Heart Failure Study Group.
        N Engl J Med. 1996; 334: 1349-1355
        • Cintron G.
        • Johnson G.
        • Francis G.
        • Cobb F.
        • Cohn J.N.
        Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure.
        Circulation. 1993; 87: VI17-VI23
        • Solomon S.D.
        • Anavekar N.
        • Skali H.
        • McMurray J.J.
        • Swedberg K.
        • Yusuf S.
        • Granger C.B.
        • Michelson E.L.
        • Wang D.
        • Pocock S.
        • Pfeffer M.A.
        • Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators
        Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients.
        Circulation. 2005; 112: 3738-3744
        • Ahmed A.
        • Aronow W.S.
        • Fleg J.L.
        Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function.
        Am Heart J. 2006; 151: 444-450
        • Curtis J.P.
        • Sokol S.I.
        • Wang Y.
        • Rathore S.S.
        • Ko D.T.
        • Jadbabaie F.
        • Portnay E.L.
        • Marshalko S.J.
        • Radford M.J.
        • Krumholz H.M.
        The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure.
        J Am Coll Cardiol. 2003; 42: 736-742
        • Shahar E.
        • Lee S.
        • Kim J.
        • Duval S.
        • Barber C.
        • Luepker R.V.
        Hospitalized heart failure: rates and long-term mortality.
        J Card Fail. 2004; 10: 374-379